CCM
REGN icon

Cribstone Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cribstone Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed -$1K – 525
2022
Q1 		$1K Buy
+1
New +$633 ﹤0.01% 392
2018
Q4 		– Sell
-7
Closed -$3K – 744
2018
Q3 		$3K Hold
7
– – ﹤0.01% 695
2018
Q2 		$2K Hold
7
– – ﹤0.01% 739
2018
Q1 		$2K Buy
+7
New +$2.44K ﹤0.01% 729

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cribstone Capital Management's REGN Position: Q2 2022 in Review

Cribstone Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 1 share — an estimated $1K sold.

Cribstone Capital Management first reported a position in REGN in Q1 2018 and held it in 4 quarters. The position peaked at $3K in Q3 2018. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Cribstone Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cribstone Capital Management sold 1 Regeneron Pharmaceuticals share in Q2 2022, an estimated $1K.
  • Cribstone Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • Cribstone Capital Management's Regeneron Pharmaceuticals position peaked at $3K in Q3 2018.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Cribstone Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.